Synthesis and Bioactivities of Leflunomide analogs
碩士 === 國防醫學院 === 藥學研究所 === 93 === Abstract Leflunomide(LEM) has been approved as a newest disease-modifying antirheumatic drug by the FDA in 1998. Being a prodrug, LEM was rapidly converted in vivo to its active metabolite MNA. The active metabolite acts by inhibiting dihydroorotate dehydrogenase,...
Main Authors: | Wu Hsiu-Hui, 吳秀慧 |
---|---|
Other Authors: | Huang Wen-Hsin |
Format: | Others |
Language: | zh-TW |
Published: |
2005
|
Online Access: | http://ndltd.ncl.edu.tw/handle/97959311808555901795 |
Similar Items
-
Synthesis and Bioactivities of Leflunomide Analogs
by: Pei-Wen Yeh, et al.
Published: (2004) -
Synthesis and anti-inflammatory activity of leflunomide analogs
by: Shyh-Bin Cheng, et al.
Published: (2003) -
Anti-inflammatory and Antiplatelet effects of Leflunomide
by: Shiu-Jen Chen, et al.
Published: (2004) -
Leflunomide in clinical practice
by: Yuriy Aleksandrovich Olyunin
Published: (2014-03-01) -
Leflunomide in clinical practice
by: Yuriy Aleksandrovich Olyunin
Published: (2014-03-01)